Strategy

Amgen board member and serial CEO Fred Hassan talks about the three levers Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.

The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?

NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.

Focusing on prevention, diagnosis, treatment, and care monitoring during the patient journey in oncology to create value for stakeholders.

What the future emergence of Amazon Pharmacy and the company’s aim to own the health experience may mean for pharma manufacturers’ engagement strategies and role in Rx delivery.

Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.

How engaging with digital influencers holds the key for medical affairs.

If the life sciences sector can support healthcare professionals to gain confidence in substituting original treatments with new biosimilars, prices will reduce and patient outcomes will be enhanced.

Implementing an efficient means of unifying disparate data and allowing teams to utilize this single source of truth data will allow them to track KPIs more effectively and get key insights when they need them.

A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.

Tips for rounding out the rough edges in crossover.

Female medical affairs leaders speak out with unique perspectives on how MSLs can provide greater value to opinion leaders.

Assessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.

Addressing the challenges faced by Global Medical Affairs teams and how they can find balance to create maximum value for their organizations.

In this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.

Dr. George Westerman talks to Michael Wong about how smarter executives will successfully lead their workforces in a post COVID-19 business environment.

Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.

While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.

Uncovering fish oil derivative’s benefit for heart health.

New hope accompanies overdue recognition in sickle cell disease fight.

The world’s most expensive drug put in context.

How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.

Amid pandemic, rely on the fundamentals.

Looking at four building blocks of success, Wolfram Lux and Simone Seiter investigate what it takes to win and be successful when commercializing an orphan drug

A look at how pharmaceutical company, Paratek is navigating the launch of a new antibiotic during the COVID-19 pandemic.